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aSupplementary Figure 1. (a,b) ERAP1 inhibition does not affect Jun or Wnt pathways. Luciferase activity of MEF
cells transfected with MMP1 luciferase reporter and C-Jun (a) or Top Flash luciferase reporter and β-Catenin (b) and
treated with increasing amounts of Leu-SH or DTT as control. Data are normalized against Renilla activity and
indicated as percentage relative to control. Statistical significance was determined with two-tailed Student’s t-test.
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Supplementary Figure 2. (a) Densitometric analysis of ERAP1 protein levels after treatment with Leu-SH. Values
represent the mean of more than three independent experiments. Statistical significance was determined with two-
sided Student’s t-test. (b) MEFs were transfected with ERAP1 and Flag-Gli1 or Flag-Gli2 or Flag-Gli3 as indicated.
Cell lysates were immunoprecipitated with an anti-Flag antibody and immunoblotted with anti-ERAP1 antibody.
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Supplementary Figure 3. (a,b) qRT-PCR analysis of βTrCP in MEFs transfected with increasing amounts of vector
encoding ERAP1 (a) or treated with the indicated amounts of Leu-SH (b). Data are normalized to endogenous
GAPDH and HPRT controls and represent the mean of three independent experiments. Statistical significance was
calculated with two-sided Student’s t-test. (c,d) Representative immunoblotting analysis of the indicated βTrCP
substrates in MEFs transfected with increasing amount of vector encoding ERAP1 (c) or treated for 24 hours with
Leu-SH at the indicated concentrations (d). ERAP1 expression was also evaluated and actin was used as loading
control.
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Supplementary Figure 4. (a) Cell lysates of WT or Ptch-/- MEFs were immunoprecipitated with an anti-Gli1 antibody
and immunoblotted with anti-phospho-PKA substrates antibody. Blot was reprobed with an anti-Gli1 antibody.
*Unspecific band. (b) Ptch-/- MEFs were treated for 6 hours with 30 μM H89 or vehicle. Gli1 expression was
evaluated and vinculin was used as loading control. Densitometry analysis of vinculin-normalized of Gli1 values of
three independent experiments was shown (rigth panel). Mean ±S.D. *P < 0.05 determined by two-tailed Student’s t-
test.
a
b
IP: IgG or Gli1
IB: Phospho-PKA substrates
140
140
Reblot: Gli1
WT Ptch-/-
CTRL IgG
WT Ptch-/-
IP
*
Vinculin
140
124
H89 +-
Gli1
IP: ERAP1
IB: USP47
IB: USP24
IB: USP22
Reblot: ERAP1
115
170
CTRL IP
190
50
USP47
USP24
USP22
ERAP1
INPUT
Supplementary Figure 5. (a,b) MEFs were transfected with ERAP1 and Flag-βTrCP and after 24h treated with
MG132 for 4h. Cell lysates were immunoprecipitated with an anti-Flag (a) or ERAP1 antibody (b) and immunoblotted
with anti-ERAP1 or anti-Flag antibody. Blots were reprobed with an anti-Flag antibody (a) or anti-ERAP1 antibody
(b). (c) MEFs were transfected with ERAP1 and cell lysate was immunoprecipitated with an ERAP1-antibody and
immunoblotted for the indicated proteins. Blots were reprobed with an anti-ERAP1 antibody.
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Supplementary Figure 6. (a) qRT-PCR analysis of Hh target genes in MB samples (pools of 3 samples for each
experimental group) excised from Gfap-Cre/Ptcfl/fl mice treated for two days with Leu-SH or vehicle as indicated in
Methods. (b) Immunoblotting Gfap-Cre/Ptcfl/fl mice analysis of Gli1 and βTrCP in MB samples from (a). Actin was
used as loading control. Mean ±S.D. **P < 0.01 calculated using two-tailed Student’s t-test.
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Supplementary Figure 7. ERAP1 affects Daoy cell growth both in vitro and in vivo .(a,b) Daoy cells were treated with
Leu-SH at the indicated concentrations. Cells were counted with trypan blue at different time point to evaluate the
viable cells growth rate (a) and the cell death percentage (b). (c) mRNA expression levels of Hh target genes of Daoy
cells treated with Leu-SH at the indicated concentrations for 48h. (d-g) Daoy cells transduced with lentiviral particles
encoding shCTRL or shERAP1. After 72h of infection cells were plated and counted with trypan blue at the indicated
time points (d). Percentage of BrdU uptake (e), expression levels of the protein involved in the Hh pathway regulation
(f) and Gli1 mRNA expression level expresssed as fold change respect to the control value (g). (h-k) NSG mice (n=8
for group) were grafted with Daoy genetically silenced for ERAP1 expression by lentiviral infection. Tumor growth was
monitored over time (h). Representative flank xenograft average volumes (lower panel) and quantification of explanted
tumors (upper panel) were shown in (i). mRNA of Hh target genes (j) and protein of Gli3 and βTrCP (k) expression
levels from tumor masses were assayed. Mean ±S.D. *P < 0.05; **P < 0.01; ***P < 0,001 determined by two-sided
Student’s t-test.
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Supplementary Figure 9. (a-d) Gene expression profile of ERAP1 (a,c) or USP47 (b,d) in molecular subgroups
of MB tumors (a,b) or in several data set of different brain tumors (c,d). Data were retrieved from R2 Genomics
Analysis and Visualization Platform (http://r2.amc.nl).
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